🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C43

Find Recruiting Clinical Trials for Melanoma

Search BRAF-mutant, immunotherapy, adjuvant, and metastatic melanoma trials — matched to your mutation status and disease stage.

🔍 Search Melanoma Trials →

About Melanoma

Melanoma is the most serious form of skin cancer, arising from melanocytes (pigment-producing cells). While it represents only about 1% of skin cancers, it causes the majority of skin cancer deaths. Melanoma has been transformed by two therapeutic revolutions: BRAF-targeted therapy (for the ~50% of melanomas with BRAF V600 mutations) and immune checkpoint inhibition (anti-PD-1, anti-CTLA-4). Together, these have changed metastatic melanoma from a disease with median survival under 12 months to one where long-term remission is achievable in a meaningful proportion of patients.

What Types of Melanoma Clinical Trials Exist?

Melanoma trials span all stages: Stage II–III adjuvant trials test checkpoint inhibitors and targeted therapies after resection to prevent recurrence. Metastatic (Stage IV) trials test new checkpoint inhibitor combinations, TIL (tumor-infiltrating lymphocyte) cell therapies, bispecific antibodies, and next-generation BRAF/MEK inhibitors. BRAF V600E/K mutation status is the critical biomarker — BRAF-mutant melanomas have targeted therapy options while BRAF wild-type tumors are treated with immunotherapy alone. PD-L1 expression and TMB (tumor mutational burden) are increasingly relevant.

Find Recruiting Melanoma Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Melanoma Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for melanoma?▾
Recruiting melanoma trials include checkpoint inhibitor combinations (anti-PD-1 + anti-CTLA-4, anti-PD-1 + anti-LAG-3), TIL cell therapy (lifileucel-based protocols), bispecific antibodies, BRAF/MEK inhibitor combinations and sequencing studies, adjuvant checkpoint inhibitor trials, and neoantigen vaccine trials.
How does BRAF mutation status affect melanoma trial eligibility?▾
BRAF V600 mutation status is the most important biomarker in melanoma. BRAF-mutant melanomas (V600E, V600K) can be treated with BRAF/MEK inhibitor combinations (dabrafenib + trametinib, vemurafenib + cobimetinib) and also respond to immunotherapy. Many trials stratify by BRAF status or specifically enroll BRAF-mutant or BRAF wild-type patients separately. Molecular testing of tumor tissue is required.
Are there melanoma trials for earlier stages (not metastatic)?▾
Yes. Stage II–III melanoma has an active adjuvant trial landscape. Adjuvant immunotherapy (nivolumab, pembrolizumab) is standard of care for high-risk resected melanoma, and trials test new adjuvant regimens, combinations, and biomarker-selected approaches. Neo-adjuvant (pre-surgery) trials are also enrolling.

Related Conditions

Lung CancerBreast CancerKidney Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.